Iodinated radiolabelable ChT ligands for diagnostics and therapy
Choline transporter (ChT) is strongly overexpressed in certain types of cancer cells, e.g. prostate carcinoma, glioma, and small-cell carcinoma. Moreover, alterations in ChT function have been linked to various neurological and psychiatric disorders. Thus, ChT represents a valuable target for diagnostic and therapeutic radiopharmaceuticals.
TECHNOLOGY (INVENTION) DESCRIPTION:
Current medicine and the field of cancer management in particular greatly and increasingly profits from radionuclide imaging methods such as positron emission tomography (PET), single photon emission computed tomography (SPECT), and planar scintigraphy (PS). We have developed a novel series of iodinated small-molecule ligands, which are applicable in diagnostics and therapy of diseases related to pathological expression/function of choline transporter. Labeling of these compounds with different radioactive isotopes of iodine enables their use not only in all of the aforementioned imaging modalities - PET (124-I), SPECT (123-I, 131-I), PS (123-I, 131-I) - but also in therapy (131-I). Our labeling procedure optimized for mild conditions would allow manufacture of radiopharmaceutical kits.
ADVANTAGES OVER EXISTING SOLUTIONS:
The two radiopharmaceuticals [11-C]choline and [18-F]fluorocholine presently used in clinical practice suffer from serious drawbacks. These drawbacks are stemming mainly from the short half-lives of applied nuclides (20 min and 110 min, respectively). The short nuclide half-lives in combination with rapid renal excretion and high organ uptake of the mentioned drugs results in a high image background and unfavorable lesion detection sensitivity. Iodine radioisotopes possess more favorable half-lives and unlike [11-C]Ch and [18-F]FCh allow combining diagnostics with therapy. Use of iodinated radiopharm. does not require an on-site cyclotron, which significantly reduces the cost of examination.
DEVELOPMENT STATUS (STAGE):
Data on cancer cell lines and ADME/Tox, in vivo biodistribution data.
IP PROTECTION STATUS:
Czech patent pending - PV 2016-117; PCT application scheduled for February 2017.
TECHNOLOGY / IP OWNERS :
Institute of Macromolecular Chemistry AS CR, v.v.i.; Palacky University Olomouc - Institute of Molecular and Translational Medicine
More information is available upon signing a CDA / NDA (Confidential Disclosure Agreement / Non-Disclosure Agreement)